Mohamad Johan - Understanding WHO scheduling recommendations for Cannabis Hemp

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/4e/93/ba/4e93baf5-bba1-3b4e-83fa-7c8c5e9e13ae/mza_1785033934116884134.jpg/600x600bb.jpg

Go Green by MHIRA

MHIRA

10 episodes

4 days ago

Learn more from a conversation with our guests to talk about hemp, cannabis, sustainability and entrepreneurship. The session is directed at different industries to understand the potential and challenges of each industry for Hemp Cannabis in Malaysia & Asian region and to provide an outlook to the general public on the current progress. The session will give a preview of the potential of Hemp Cannabis in Malaysia and methods in which each individual can collaborate and be involved.

Entrepreneurship

Business

RSS

All content for Go Green by MHIRA is the property of MHIRA and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Entrepreneurship

Business

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/12631215/12631215-1612846532621-4273f553fb783.jpg

Mohamad Johan - Understanding WHO scheduling recommendations for Cannabis Hemp

Go Green by MHIRA

40 minutes

4 years ago

Mohamad Johan - Understanding WHO scheduling recommendations for Cannabis Hemp

Mohamad Johan, Founder & President of MHIRA

Understanding WHO scheduling recommendations for Cannabis Hemp

The U.N. created the Commission on Narcotic Drugs (CND) to monitor and amend the designations assigned to substances, which is where the WHO comes in. It’s required by international law to research medical and scientific benefits and risks associated with substances such as cannabis. In turn, the CND implements the WHO’s recommendations when making scheduling decisions regarding a plant or substance. So how significant was the WHO’s recent recommendations on cannabis to the CND?

In earliest be deleted 2019, the WHO recommended the CND reschedule cannabis and that cannabis “r from Schedule 4 of the Single Convention on Narcotics Drugs (1961),” (the most restrictive category, like the CSA’s Schedule I). In addition, the report recommended that tetrahydrocannabinol (THC) be “deleted from the Convention on Psychotropic Substances (1971) and added to Schedule 1 of the Single Convention on Narcotics Drugs (1961).” Regarding CBD, the report recommended that cannabis extracts containing up to .2% THC not be scheduled within the drug control conventions. This signified a monumental change and the codifying of the medicinal value of cannabis. Further, it provided clarity around the international trade of CBD products.